Donor-Related Risk Factors for Graft Decompensation Following Descemet’s Stripping Automated Endothelial Keratoplasty

Sota Nishisako¹, Takefumi Yamaguchi², Masatoshi Hirayama², Kazunari Higa¹, Dai Aoki¹, Chiaki Sasaki¹, Hisashi Noma³ and Jun Shimazaki¹,²*

¹Cornea Center and Eye Bank, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan, ²Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan, ³Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan

Aims: To identify donor-related risk factors associated with graft endothelial failure and postoperative endothelial cell density (ECD) reduction after Descemet’s stripping automated endothelial keratoplasty (DSAEK).

Methods: This was a single-center retrospective study conducted from July 2006-December 2016. We included 584 consecutive eyes (482 patients) that underwent DSAEK for the treatment of laser iridotomy-related bullous keratopathy (192 eyes), pseudophakic bullous keratopathy (137 eyes), regraft (96 eyes), Fuchs’ endothelial corneal dystrophy (FECD; 59 eyes) and others (100 eyes). Twenty-three donor- and recipient-related risk factors potentially associated with graft failure and ECD reduction were assessed using Cox hazard models and linear mixed effect models.

Results: The median age of the patients was 73.5 years (male; 35.6%). After DSAEK, ECD decreased from 2,674 cells/mm² (95% confidence interval [CI]; 2,646–2,701) to 1,132 (1,076–1,190) at 12 months and 904 (845–963) at 24 months (P < 0.001). Fifty-five eyes (9.4%) had graft endothelial failure without rejection. This failure was associated with donor pseudophakic lens status (hazard ratio [HR]; 2.67, CI; 1.50–4.76, P = 0.001) and preoperative endothelial folds (HR; 2.82, CI; 1.20–6.62, P = 0.02). The incidence of graft endothelial failure in non-FECD patients was significantly higher among those receiving donor grafts with a pseudophakic lens status and preoperative presence of endothelial folds (P < 0.001). Postoperative ECD loss was significantly greater in eyes with these risk factors compared to those without (P = 0.007).

Conclusions: Pseudophakic status and/or presence of preoperative endothelial folds are the significant donor risk factors for endothelial failure in non-FECD patients.

Keywords: donor-related risk factors, donor pseudophakic lens status, preoperative endothelial folds, Descemet's stripping automated endothelial keratoplasty (DSAEK), non-fuchs' endothelial corneal dystrophy patients
INTRODUCTION

Corneal endothelial dysfunction is one of the leading causes of blindness among patients with corneal diseases (1). Selective replacement of the damaged corneal endothelium by Descemet’s stripping automated endothelial keratoplasty (DSAFEK) or Descemet’s membrane endothelial keratoplasty (DMEK) allow rapid visual recovery (2, 3), resistance to trauma, and minimum astigmatism in comparison with conventional penetrating keratoplasty (PKP), and were able to improve the prognosis of corneal transplantation for bullous keratopathy (BK) eyes (4–6). However, late corneal endothelial failure owing to chronic loss of corneal endothelial cells remains a clinically relevant issue that should be addressed to improve the long-term prognosis of endothelial keratoplasty (7).

Previous clinical studies have shown various risk factors, including donor and recipient factors, associated with endothelial cell density (ECD) loss and graft failure (8–13). However, these results for donor risk factors after DSAFEK were obtained in the United States or Europe, where Fuchs’ endothelial corneal dystrophy (FECD) is the most common indication in recipient cohorts. In contrast, the indications for DSAFEK in Asian countries are different: 70% of endothelial keratoplasties in these countries were performed for treating pseudophakic bullous keratopathy (PBK) or laser-iridotomy-related bullous keratopathy (LIBK), and the number of cases involving FECD accounted for approximately 10% of all transplants (14–16). Although a thorough assessment of donor-related risk factors to improve graft survival after DSAFEK is essential, the data for cases involving non-FECD corneal edema disease in Asian countries have been scarce. Therefore, this study aimed to evaluate donor-related factors that may be associated with corneal endothelial failure and reduction in ECD after DSAFEK, especially for recipients with non-FECD.

MATERIALS AND METHODS

This study was conducted according to the tenets of the Declaration of Helsinki, and it received approval from the Institutional Ethics Reviewer Board of Tokyo Dental College Ichikawa General Hospital (Acceptance No. I 18-19). Our Institutional Review Board waived the requirement for informed consent for this retrospective study. Patient data were anonymized before access and/or analysis.

Data Collection and Analysis

From July 2006 through December 2016, 587 eyes of 485 patients who underwent DSAFEK at the Tokyo Dental College Ichikawa General Hospital were enrolled. All eligible donor corneas met the medical standards of the Eye Bank Association of America or Cornea Center and Eye Bank (CCEB, Chiba, Japan). All domestic corneas were donated to Japanese eye banks and were transported to Tokyo Dental College Ichikawa General Hospital via CCEB. Imported corneas were prepared at an eye bank in the United States of America (Sight-Life, Seattle, WA) and were shipped internationally by airplane. All donor corneas were preserved in a viewing storage chamber and kept in cold-storage for refrigerated/on ice, and re-bubbling.

| TABLE 1 | Demographics of all samples (N = 584). |
| Donor and donor cornea characteristics |
| Donor age, median (IQR), range, y | 66.0 (58, 72), 18–96 |
| Donor sex, male, n (%) | 373 (63.9) |
| Imported graft, n (%) | 427 (73.1) |
| History of diabetes mellitus, n (%) | 140 (24.0) |
| Cigarettes smoking, n (%) | 323 (55.3) |
| Alcohol consumption, n (%) | 206 (35.3) |
| Drug abuse, n (%) | 73 (12.5) |
| Donor sex, male, n (%) | 83 (14.2) |
| Phakic | 487 (84.0) |
| IOL | 97 (16.6) |
| Cause of death, n (%) |
| Cardiac disease | 148 (25.3) |
| Cancer | 147 (25.2) |
| Cerebrovascular accident | 86 (14.8) |
| Respiratory disease | 99 (17.0) |
| Others | 104 (17.7) |
| Refrigerated/on ice, n (%) | 343 (58.7) |
| Time from death to the preservation, median (IQR), range, h | 8.0 (5.9, 11.9), 1.8–26.9 |
| Time from death to operation, median (IQR), range, d | 6.9 (6.0, 7.7), 2.0–9.6 |
| Graft ECD, median (IQR), range, cells/mm2 | 2,637 (2,415, 2,921), 2,010–3,812 |
| Endothelial folds, n (%)* |
| None | 157 (26.9) |
| Mild to moderate | 427 (73.1) |
| Recipient and surgical characteristics |
| Recipient age at DSAFEK, median (IQR), range, y | 73.5 (67, 79), 15–99 |
| Recipient sex, male, n (%) | 208 (35.8) |
| Etiology, n (%) |
| FECD | 9 (1.0) |
| LIBK | 192 (32.9) |
| PBK | 137 (23.5) |
| Regraft† | 96 (16.4) |
| Others | 100 (17.1) |
| Recipient lens status at DSAFEK, n (%) |
| Phakic | 244 (41.8) |
| IOL/Aphakic | 340 (58.2) |
| Simultaneous cataract surgery, n (%) | 189 (32.4) |
| Others | 79 (13.5) |
| Central graft thickness, median (IQR), range, µm² | 143 (123, 161), 53–270 |

(Continued)
Donor Factors Affecting DSAEK Prognosis

TABLE 1 | Continued

| Graft diameter, n (%), mm |
|--------------------------|
| 6.75–7.75 | 144 (24.7) |
| 8.0–8.75 | 440 (75.3) |

DSAEK, Descemet's stripping automated endothelial keratoplasty; ECD, endothelial cell density; FECD, Fuchs' endothelial corneal dystrophy; IOL, intraocular lens; IQR, interquartile range; LASIK, laser-assisted in situ keratomileusis; LKB, laser-induced keratotherapeutic bulbar keratopathy; PBK, pseudophakic bullous keratopathy.

Grafts without folds were defined as having "no graft folds," "mild graft folds" were defined by the presence of graft folds limited to <25% of the area of the total cornea, and "moderate graft folds" were defined by the presence of graft folds that occupied more than 25% of the area of the total cornea.

1 Regraft is included in re-DSAEK (6 eyes), post penetrating keratoplasty (36 eyes), post-deep anterior lamellar keratoplasty (2 eyes) and post-Descemet's membrane endothelial keratoplasty (2 eyes).

2 Central graft thickness data was obtained in 503 eyes.

corneal preservation medium (Optisol-GS solution; Bausch and Lomb Surgical, Rochester, NY, USA) at a temperature of 2°-8°C. In the eye bank, the central corneal ECD of all tissues was measured using specular microscopy and slit-lamp microscopy was performed by eye bank technicians or eye doctors to evaluate transplant suitability (i.e., epithelial/stromal/endothelial cells/endothelial folds/cutting issue). ECDs of all the grafts used for DSAEK in this study were more than 2,000 cells/mm² preoperatively. The DSAEK procedure was performed using the double-glide technique in a standardized manner (17, 18). Briefly, Descemet stripping was performed using a reverse-bent Sinsky hook (ASICO, Westmont, IL), and the recipient's endothelium and Descemet's membrane were carefully removed with forceps. A precut donor tissue was trephinated, and it was gently inserted into the anterior chamber using the Bausch glide spatula (ASICO). Air was carefully injected into the anterior chamber to unfold the graft. Ten minutes after the air injection, half of the air was replaced with a balanced salt solution (Alcon, Fort Worth, TX). Postoperatively, topical 0.1% betamethasone (Sanbetazon; Santen, Osaka, Japan) qid was prescribed for 6 months. Six months after DSAEK, 0.1% fluorometholone (Flumetholone 0.1; Santen) was prescribed three times a day for up to 12 months after surgery. ECD was measured by blinded orthoptists at 1, 3, 6, 12, and 24 months after DSAEK using a specular microscopy system (EM-4000; TOMEY, Nagoya, Japan). Approximately 50 cells were analyzed for mean ECD (17). In some patients, direct ECD measurement was difficult due to corneal edema or interface irregularity. Therefore, ECD in eyes with irreversible edema due to endothelial decompensation was defined as 300 cells/mm² as previously reported (7, 17, 19). To evaluate the association between postoperative ECD and risk factors, we analyzed ECD as absolute ECD and percentage of 24-month ECD loss (%ECD loss = [24-month ECD - graft ECD]/graft ECD × 100) (10). Graft survival periods were defined as from DSAEK surgery to the date of the clinical visit when irreversible corneal edema refractory to subsequent topical steroid use was noted. Graft survival time or time to censor (end of the study/loss of contact/withdrawal from the study) was calculated as the number of days between the date of DSAEK surgery and endothelial failure or censor. Three eyes of three patients with a follow-up period of < 1 month were excluded. We treated 13 eyes involving graft rejection episodes, four eyes with ocular infections, and nine eyes in which the procedure failed because of ocular surface complications or irregular graft thickness as censors. A total of 584 eyes of 482 patients were finally included. We selected the following 15 variables based on previous studies and our knowledge of donor-related factors (7–13) that can potentially affect graft survival and reduction in ECD after DSAEK: donor age, sex, domestic/imported graft, history of diabetes mellitus, cigarette smoking, alcohol consumption, drug abuse, history of laser-assisted in situ keratomileusis, lens status (phakic/intraocular lens [IOL]), cause of death (cardiac disease/cancer/cerebrovascular accident/respiratory disease/other diseases), refrigerated body/eyes, time from death to the preservation, time from death to operation, ECD, and graft endothelial folds (none/mild/moderate). The graft endothelial fold severity grade for each patient was determined based on slit-lamp microscopic examination findings before DSAEK. Briefly, grafts without folds were defined as having “no graft folds,” “mild graft folds” were defined by the presence of graft folds limited to <25% of the area of the total cornea, and “moderate graft folds” were defined by the presence of graft folds occupying more than 25% of the area of the total cornea. Among recipient/surgical factors, we evaluated age, sex, etiologies of bulbar keratopathy, lens status at DSAEK, simultaneous cataract surgery, re-bubbling, central graft thickness, and graft diameter. Thus, a total of 23 potential preoperative risk factors (15 donor-related and eight recipient-related factors) were evaluated (Table 1).

Statistical Analysis

The required sample size was based on previous studies (5, 7–13) which estimated that approximately 10% of grafts used DSAEK develop graft failure postoperatively. Given approximately 30% of withdrawal from the study, we determined that a sample size of at least 521 would provide 80% power to detect a difference in a hazard ratio of 0.60 or greater at an alpha value of 0.05 (two-sided). The cumulative probability of graft survival at the 2-year follow-up was calculated using the Kaplan–Meier method. In survival analysis, the collected categorical data were transformed into dummy and continuous variables and dichotomized with the median for use as categorical data. Recipient etiologies were investigated under non-FECD groups. A log-rank test was used to assess the association of each baseline factor with endothelial failure in univariate analysis. Factors with P < 0.05 in univariate analysis underwent proportional hazard analyses by log-log plot and Schoenfeld residuals tests and were included in multivariate Cox proportional hazard regression analysis for estimation of the independent predictors of endothelial failure in all patients. The prognostic model was prepared by combining the extracted risk factors (20, 21). Cumulative probability of graft survival was compared between the grafts with no risk factors and grafts with one or two risk factors. The Kaplan–Meier curves were plotted with non-FECD.

To evaluate the associations between postoperative ECD changes and risk factors adjusted for the effects of patient
| Prognostic factor                      | n   | 2-year graft survival (95% CI) | Log-rank test | Multivariate models* |
|--------------------------------------|-----|------------------------------|--------------|---------------------|
|                                      |     |                             | P            | HR (95% CI)         | P       |
| **Donor age, y**                     |     |                              |              |                     |
| 18–65                                | 281 | 0.91 (0.86–0.94)             | 0.04         | 1 [reference]       | 0.48    |
| 66–96                                | 303 | 0.85 (0.80–0.89)             |              | 1.23 (0.69–2.19)    | 0.48    |
| **Donor sex**                        |     |                              |              |                     |
| Male                                 | 373 | 0.90 (0.86–0.93)             | 0.13         |                     |         |
| Female                               | 211 | 0.86 (0.79–0.90)             |              |                     |         |
| **Imported graft**                   |     |                              |              |                     |
| No                                   | 157 | 0.89 (0.85–0.92)             | 0.48         |                     |         |
| Yes                                  | 427 | 0.87 (0.79–0.92)             |              |                     |         |
| **History of diabetes mellitus**    |     |                              |              |                     |
| No                                   | 444 | 0.91 (0.87–0.93)             | 0.007        | 1 [reference]       | 0.09    |
| Yes                                  | 140 | 0.81 (0.72–0.87)             |              | 1.63 (0.93–2.86)    | 0.09    |
| **Cigarettes smoking**               |     |                              |              |                     |
| No                                   | 323 | 0.87 (0.82–0.91)             | 0.42         |                     |         |
| Yes                                  | 261 | 0.90 (0.84–0.93)             |              |                     |         |
| **Alcohol consumption**              |     |                              |              |                     |
| No                                   | 378 | 0.87 (0.82–0.90)             | 0.22         |                     |         |
| Yes                                  | 206 | 0.91 (0.85–0.94)             |              |                     |         |
| **Drug abuse**                       |     |                              |              |                     |
| No                                   | 511 | 0.89 (0.85–0.91)             | 0.55         |                     |         |
| Yes                                  | 73  | 0.85 (0.72–0.92)             |              |                     |         |
| **History of LASIK**                 |     |                              |              |                     |
| No                                   | 550 | 0.88 (0.85–0.91)             | 0.92         |                     |         |
| Yes                                  | 34  | 0.89 (0.70–0.96)             |              |                     |         |
| **Donor lens status**                |     |                              |              |                     |
| Phakic                                | 487 | 0.91 (0.88–0.94)             | <0.001       | 1 [reference]       | 0.001   |
| IOL                                  | 97  | 0.73 (0.62–0.81)             |              | 2.67 (1.50–4.76)    | 0.001   |
| **Cause of death**                   |     |                              |              |                     |
| Cancer                               | 147 | 0.87 (0.83–0.90)             | 0.22         |                     |         |
| Non-cancer                           | 437 | 0.93 (0.86–0.96)             |              |                     |         |
| **Refrigerated/on ice**              |     |                              |              |                     |
| No                                   | 241 | 0.89 (0.84–0.93)             | 0.68         |                     |         |
| Yes                                  | 343 | 0.88 (0.83–0.91)             |              |                     |         |
| **Time from death to the preservation, h** |   |                              |              |                     |
| 1.8–7.9                              | 287 | 0.89 (0.84–0.92)             | 0.49         |                     |         |
| 8.0–26.9                             | 297 | 0.87 (0.82–0.91)             |              |                     |         |
| **Time from death to operation, d**  |     |                              |              |                     |
| 1.8–6.8                              | 289 | 0.88 (0.82–0.91)             | 0.47         |                     |         |
| 6.9–9.6                              | 295 | 0.89 (0.84–0.92)             |              |                     |         |
| **Graft ECD, cells/mm²**             |     |                              |              |                     |
| 2.010–2.636                          | 292 | 0.85 (0.80–0.89)             | 0.06         |                     |         |
| 2.637–3.812                          | 292 | 0.91 (0.87–0.94)             |              |                     |         |
| **Endothelial folds**                |     |                              |              |                     |
| None                                 | 157 | 0.95 (0.89–0.98)             | 0.003        | 1 [reference]       | 0.02    |
| Mild to moderate                     | 427 | 0.86 (0.81–0.89)             |              | 2.82 (1.20–6.62)    | 0.02    |

(Continued)
TABLE 2 | Continued

| Prognostic factor | \( n \) | 2-year graft survival (95% CI) | Log-rank test | Multivariate models* |
|------------------|----------|-------------------------------|--------------|---------------------|
| **Recipient age at DSAEK, y** | | | | |
| 15–72            | 259      | 0.87 (0.82–0.91)              | 0.56         |                     |
| 73–92            | 325      | 0.89 (0.84–0.92)              |              |                     |
| **Recipient sex** | | | | |
| Male             | 208      | 0.85 (0.78–0.90)              | 0.23         |                     |
| Female           | 376      | 0.90 (0.86–0.93)              |              |                     |
| **Etiology**     | | | | |
| FECD             | 59       | 0.98 (0.85–1.00)              | 0.04         | 1 [reference]       |
| Non-FECD         | 525      | 0.87 (0.83–0.90)              | 5.50 (0.76–39.93) | 0.09 |
| **Recipient lens status** | | | | |
| Phakic           | 244      | 0.90 (0.84–0.93)              | 0.53         |                     |
| IOL/Aphakic      | 340      | 0.88 (0.83–0.91)              |              |                     |
| **Simultaneous CS** | | | | |
| No               | 395      | 0.87 (0.83–0.90)              | 0.15         |                     |
| Yes              | 189      | 0.92 (0.86–0.95)              |              |                     |
| **Re-bubbling** | | | | |
| No               | 505      | 0.88 (0.85–0.91)              | 0.18         |                     |
| Yes              | 79       | 0.82 (0.67–0.91)              |              |                     |
| **Central graft thickness, \( \mu \text{m}^2 \)** | | | | |
| 53–130           | 167      | 0.85 (0.75–0.91)              | 0.93         |                     |
| 131–270          | 336      | 0.89 (0.84–0.92)              |              |                     |
| **Graft diameter, mm** | | | | |
| 6.75–7.75        | 144      | 0.89 (0.85–0.91)              | 0.80         |                     |
| 8.00–8.75        | 440      | 0.89 (0.81–0.93)              |              |                     |

CI, confidence interval; CS, cataract surgery; DSAEK, Descemet’s stripping automated endothelial keratoplasty; ECD, endothelial cell density; FECD, Fuchs’ endothelial corneal dystrophy; HR, hazard ratio; LASIK, laser-assisted in situ keratomileusis; IOL = intraocular lens.

* Cox proportional hazard regression analysis.
† Grafts without folds were defined as having “no graft folds,” “mild graft folds” were defined by the presence of graft folds limited to <25% of the area of the total cornea, and “moderate graft folds” were defined by the presence of graft folds occupying more than 25% of the area of the total cornea.

RESULTS

Demographics

In 584 eyes of 482 patients (Table 1), the median follow-up period was 24 months (interquartile range [IQR], 12–24 months). The recipients’ age at DSAEK ranged from 15 to 99 years (median, 73.5 years), and 208 (35.6%) were male, while 582 were Asian (99.9%). The etiologies of BK included LIBK in 192 eyes (32.9%), PBK in 137 eyes (23.5%), regraft (re-DSAEK, 56 eyes [58.3%]; post-PKP, 36 eyes, [37.5%]; post-deep anterior lamellar keratoplasty, two eyes, [2.1%] and post-DMEK, two eyes, [2.1%]) in 96 eyes (16.4%), FECD in 59 eyes (10.1%), and other conditions (birth injury, chronic uveitis, endotheliitis, etc.) in 100 eyes (17.1%). The recipients’ lens status at DSAEK was pseudophakic in 340 eyes (58.2%), and simultaneous DSAEK and cataract surgery was performed in 189 eyes (32.4%). Median central graft thickness was 143 \( \mu \text{m} \) (range, 53–270 \( \mu \text{m} \)) and the most common graft diameter was 8.0 mm in the current study. There were 373 (63.9%) male donors aged 18–96 years (median, 66.0 years). A total of 427 corneas (73.1%) were
Graft Survival and Cox Proportional Hazards Analysis

During the 2-year follow-up period, endothelial failure occurred in 55 eyes (9.4%). The cumulative probability of endothelial failure after DSAEK in the entire cohort was 0.94 (95% confidence interval [CI], 0.91–0.96) at 1 year and 0.88 (95% CI, 0.84–0.91) at 2 years (Supplementary Figure 1). Among the 23 variables selected as potential preoperative risk factors and tested in a univariate analysis using the log-rank test, donor age ($P = 0.04$), history of diabetes mellitus ($P = 0.007$), donor lens status ($P < 0.001$), endothelial folds ($P = 0.003$), and etiology ($P = 0.04$) were found to be statistically significant. These five variables were added to a multivariate model. Cox proportional hazard regression analysis revealed that donor lens status (IOD, hazard ratio [HR], 2.67; 95% CI, 1.50–4.76; $P = 0.001$) and endothelial folds (mild to moderate, HR, 2.82; 95% CI, 1.20–6.62; $P = 0.02$) were risk factors associated with endothelial failure (Table 2).

Figure 1 shows the influence of pseudophakic donor lens state and endothelial folds on graft survival in non-FECD eyes. In eyes with non-FECD, the outcome for grafts with one or two risk factors was significantly worse than that for those with no risk factor (one risk factor: HR, 14.8; 95% CI, 2.03–108; $P = 0.008$; two risk factors: HR, 33.1; 95% CI, 4.40–248; $P = 0.001$).

Endothelial Cell Density Analysis

Endothelial images were obtained and analyzable in 332 eyes (56.8%) at 1 month, 415 eyes (71.1%) at 3 months, 442 eyes (75.6%) at 6 months, 454 eyes (77.7%) at 12 months, and 383 eyes (65.5%) at 24 months after DSAEK. Mean postoperative ECD was associated with postoperative time and decreased from 2,674 cells/mm² (95% CI, 2,646–2,701) to 1,447 (95% CI, 1,377–1,516) at 1 month, 1,328 (95% CI, 1,269–1,387) at 3 months, 1,255 (95% CI, 1,198–1,311) at 6 months, 1,132 (95% CI, 1,076–1,190) at 12 months, and 904 (95% CI, 845–963) at 24 months ($P < 0.001$ at all timepoints, Figure 2). Factors associated with postoperative ECD reduction are shown in Table 3 and Supplementary Table 1. In a univariate model, donor age ($P = 0.08$), donor lens status ($P = 0.02$), graft ECD ($P = 0.07$), endothelial folds ($P = 0.04$), recipient sex ($P = 0.05$) and etiology ($P = 0.06$) had statistically significant association with postoperative ECD. Multivariable models showed that the risk factors independently associated with %ECD loss included donor lens status ($P < 0.001$), endothelial folds ($P = 0.002$) and etiology ($P = 0.001$). When the patients were stratified based on graft risk factors (pseudophakic donor lens state and endothelial folds), ECD after DSAEK was significantly greater in eyes receiving grafts from phakic eyes and without preoperative endothelial folds compared to those receiving grafts from pseudophakic eyes and/or with preoperative endothelial folds, in the mixed effect model adjusted with etiology ($P = 0.007$, Table 4).

DISCUSSION

We identified donor lens status and preoperative graft endothelial folds as risk factors associated with graft endothelial failure and ECD reduction after DSAEK. Furthermore, we demonstrated...
TABLE 3  | Factors associated with postoperative endothelial cell density.

| Prognostic factor                  | n   | Mean ECD at 24-month (95% CI) | p      | Mean %ECD loss at 24-month (95% CI) | p      |
|-----------------------------------|-----|------------------------------|--------|-----------------------------------|--------|
| **Donor age, y**                  |     |                              |        |                                    |        |
| 18–59                             | 107 | 992 (883–1,100)              | 0.08   | 63.4 (59.6–67.3)                  |        |
| 60–69                             | 128 | 981 (870–1,092)              |        | 64.1 (60.3–68.0)                  | 0.21   |
| 70–79                             | 116 | 767 (672–862)                |        | 70.7 (67.1–74.1)                  |        |
| 80–95                             | 32  | 799 (577–1,022)              |        | 71.3 (64.0–78.7)                  |        |
| **Donor lens status**             |     |                              |        |                                    |        |
| Phakic                            | 312 | 967 (900–1,033)              | 0.02   | 64.3 (61.9–66.6)                  | <0.001 |
| IOL                               | 71  | 628 (522–734)                |        | 76.5 (72.7–80.2)                  |        |
| **Graft ECD, cells/mm²**          |     |                              |        |                                    |        |
| 2,010–2,499                       | 111 | 669 (590–747)                |        | 70.8 (67.3–74.2)                  |        |
| 2,500–2,749                       | 123 | 845 (752–938)                | 0.07   | 67.4 (63.8–71.0)                  | 0.08   |
| 2,750–2,999                       | 75  | 1013 (881–1,145)             |        | 64.7 (60.1–69.3)                  |        |
| 3,000–3,812                       | 74  | 1244 (1,073–1,414)           |        | 60.5 (54.9–66.0)                  |        |
| **Endothelial folds§**            |     |                              |        |                                    |        |
| None                              | 105 | 1069 (959–1,179)             | 0.04   | 60.2 (56.2–64.3)                  | 0.002  |
| Mild to moderate                  | 278 | 842 (773–911)                |        | 68.9 (66.5–71.3)                  |        |
| **Recipient sex**                 |     |                              |        |                                    |        |
| Male                              | 133 | 828 (729–927)                | 0.05   | 69.4 (65.9–72.8)                  | 0.07   |
| Female                            | 250 | 944 (871–1,018)              |        | 65.0 (62.4–67.6)                  |        |
| **Etiology**                      |     |                              |        |                                    |        |
| FECD                              | 35  | 1245 (1,043–1,448)           | 0.06   | 54.7 (47.8–61.6)                  | 0.001  |
| Non-FECD                          | 348 | 867 (808–931)                |        | 67.7 (65.6–69.8)                  |        |

CI, confidence interval; ECD, endothelial cell density; FECD, Fuchs’ endothelial corneal dystrophy; IOL, intraocular lens.
*Adjusted for recipient and surgeon (random effect).
†The interaction of potential risk factors and postoperative time were analyzed.
‡The percentage ECD loss at 24-month is calculated as (24-month ECD – graft ECD)/graft ECD × 100.
§Grafts without folds were defined as having “no graft folds,” “mild graft folds” were defined by the presence of graft folds limited to <25% of the area of the total cornea, and “moderate graft folds” were defined by the presence of graft folds occupying more than 25% of the area of the total cornea.
Bold numbers indicate P < 0.05.

that these risk factors were clinically relevant especially in non-FECD and not in FECD, since these were associated with endothelial failure after DSAEK in non-FECD eyes. Although the prognosis of endothelial keratoplasty has been reported to be poor in eyes with PBK (8, 10, 12) especially in BK eyes after glaucoma surgery, in comparison with FECD (7, 12, 22), grafting is the only solution for such eyes with graft failure. Our results suggested that selecting better grafts with no endothelial folds or from phakic eyes for non-FECD patients may prolong graft survival after DSAEK. Our results also indicated that differences in imported or domestic donors did not have an adverse influence on endothelial failure after DSAEK.

Corneal transplants are performed in 116 countries, and imported grafts are used in 70 countries (23). The international organ-sharing program for corneal transplants has successfully grown because corneal tissue can be preserved for more than 1 week (24). Thus, understanding the donor-related risk factors from the global/transnational perspective and optimization of corneal donor tissues is important for both exporting and importing countries.

Previous studies identified several factors, including lower graft ECD (10, 12), history of glaucoma surgery (12, 13, 25), preoperative diagnosis (8, 10, 12), presence of donor diabetes mellitus (8, 10), preservation time of donor tissues (11), pre-existing iris damage (7), age (13, 26), race (4), sex (22, 26), graft size (7, 27), and pre-lamellar dissection corneal thickness (9), as risk factors for graft failure and/or rapid ECD loss after DSAEK. In contrast, long-term graft survival is known to be greater in eyes with relatively healthy peripheral endothelial cells (i.e., FECD/keratoconus) than those with BK (28, 29). Endothelial cells may migrate from the donor to the recipient eyes without peripheral endothelium (i.e., non-FECD), resulting in lower graft ECD and earlier graft failure, whereas ECD is greater in the periphery than in the center and peripheral regions of the cornea and cell migration from the host to the donor graft have been documented in corneal transplants (27, 29, 30). In the current study, we revealed that graft survival in eyes with non-FECD was significantly greater in eyes from donors with a phakic eye (HR: 2.67) and no endothelial folds (HR: 2.82). Furthermore, postoperative ECD decrease was significantly associated with donor lens status (IOL) and endothelial folds.
We identified pseudophakic donor lens status as a risk factor associated with ECD reduction and graft de-compensation after DSAEK, in contrast, the recipients’ lens status did not show a statistically significant difference. This may be related to the relatively short follow-up period of 2 years after DSAEK. The annual ECD reduction rate in normal eyes is 0.9%, which can increase up to 2.5% per year after cataract surgery (31). Kawai et al. reported elevated levels of inflammatory cytokines such as interleukin-8 and monocyte-chemotactic protein-1 after cataract surgery (32). Our recent prospective studies have shown that an aqueous humor (AqH) microenvironment with elevated levels of inflammatory cytokines is associated with rapid loss of ECD after PKP and DSAEK (17, 18, 25, 33, 34). Our multi-omics analyses of human corneal endothelial cells identified stress-induced cell senescence as an upregulated biological process in BK (35). Collectively, these results suggest that the pseudophakic donor corneal endothelium shows deterioration in quality, such as cell aging or vulnerability to the pathological microenvironment in the AqH, that potentially leads to rapid ECD loss and endothelial failure after DSAEK.

In the current study, the preoperative presence of graft folds was associated with endothelial failure and lower ECD after DSAEK. Previous studies have reported the existence of dead cells in donor corneal endothelium preserved in Optisol-GS and stored at a temperature between 4°C and 8°C before transplantation (36). Corneal folding has been shown to be significantly correlated with a reduction in corneal endothelial cells, and various studies using cell staining techniques have observed a higher concentration of dead/apoptotic endothelial cells along areas with corneal folds (37, 38). We checked the ECD before surgeries in all donor grafts, but the area of ECD measurement is very limited, approximately 0.24 × 0.35 mm (39), and ECD cannot be measured in the area with endothelial folds. A series of these studies suggested the difference between ECD values obtained by eye bank specular microscopy and the actual viable endothelial cells on the donor graft. The origin/mekanism of donor corneal folds has not been closely explored (40). In our sub-analysis, we found that donor age and time from death to the preservation were associated with the severity grade of the graft endothelial folds (Supplementary Table 2). There was no statistically significant difference between fold severe levels (mild folds vs. moderate folds) in endothelial failure after DSAEK ($p = 0.91$, data not shown). Further studies are necessary to evaluate the association between the presence of graft folds and reduction in viable corneal endothelial cells. Other potential risk factors discussed in previous studies (2, 4, 7–13, 22, 26, 27) were not associated with endothelial failure in this study: such as donor age ($P = 0.48$, in graft survival analysis), donor sex ($P = 0.13$), history of diabetes mellitus ($P = 0.09$), graft ECD ($P = 0.06$), gender matching ($P = 0.12$, data not shown), re-bubbling ($P = 0.18$), graft thickness ($P = 0.93$), and graft diameter ($P = 0.80$). This may have reflected differences in the cohort of recipients.

This study had some limitations. First, heterogeneous etiologies, such as FEDC, PBK, LIBK, and regraft, could potentially have caused bias. We found that pseudophakic donor lens status/preoperative endothelial folds were risk factors for poor prognosis of DSAEK in the non-FECD group. Further analysis that stratified the patients based on etiology for BK was attempted. DSAEK using a graft from pseudophakic donor eyes with preoperative endothelial folds showed a trend of poor prognosis in a non-FECD group, but there was no statistically significant difference for BK other than LIBK (Supplementary Figure 2). A larger sample size and longer follow-up period are needed to further assess risk factors and donor-recipient matching. Second, almost all the subjects in this study were Japanese, and future studies will be needed to substantiate the results in other populations. Third, we could not identify the exact pathological mechanism involved in ECD loss and endothelial failure in eyes with these risk factors. We recently showed that pathological alterations in the microenvironment of AqH due to iris damage predisposed to ECD loss via exacerbated stress-induced cell senescence (35).

In conclusion, grafts from pseudophakic donor eyes with preoperative endothelial folds are identified as risk factors for endothelial failure after DSAEK in recipients with non-FECD. The results of this study suggest that optimization of corneal donor tissues for patients undergoing endothelial keratoplasty is important, especially for non-FECD patients.

### TABLE 4 | Endothelial cell density after Descemet’s stripping automated endothelial keratoplasty by graft-related risk factors.

| Postoperative time | No risk factor* | One risk factor | Two risk factors |
|--------------------|----------------|----------------|-----------------|
| Mean (95% CI)      | n              | Mean (95% CI)  | n               | Mean (95% CI)  |
| Graft              | 108            | 2,717 (2,651–2,783) | 321 | 2,677 (2,639–2,714) | 155 | 2,638 (2,586–2,690) |
| 1 month            | 70             | 1,639 (1,508–1,770) | 180 | 1,461 (1,366–1,557) | 82  | 1,251 (1107–1,395) |
| 3 months           | 78             | 1,552 (1,429–1,674) | 225 | 1,316 (1,237–1,396) | 112 | 1,197 (1078–1,315) |
| 6 months           | 83             | 1,507 (1,386–1,628) | 238 | 1,258 (1,183–1,334) | 121 | 1,074 (966–1,183) |
| 12 months          | 88             | 1,454 (1,319–1,589) | 244 | 1,114 (1,039–1,188) | 122 | 940 (836–1,044) |
| 24 months          | 73             | 1,186 (1,033–1,298) | 200 | 931 (847–1,014) | 110 | 682 (589–776) |

CI, confidence interval.
*The risk factors are pseudophakic donor lens status and severe endothelial folds.
† Analyzed with a linear mixed-effect model adjusted for etiology (fixed effect) and recipient and surgeon (random effect).
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Ethics Reviewer Board of Tokyo Dental College Ichikawa General Hospital (Acceptance No. I 18-19). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SN and TY had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis, study concept and design, and drafting of the manuscript. JS, TY, MH, HN, JS, and KH critical revision of the manuscript for important intellectual content. SN, TY, and HN statistical analysis. JS and SN obtained funding. JS, TY, and MH study supervision. All authors acquisition, analysis, or interpretation of data and administrative, technical, or material support.

FUNDING

This study received funding from a Novartis Research Grant. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

ACKNOWLEDGMENTS

We thank Editage company for English language editing.

MEETING PRESENTATION

Presented at the Japan Cornea Conference, Tokyo, Japan, April 2020.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.810536/full#supplementary-material

REFERENCES

1. Eye Bank Association of America. 2019 Eye Banking Statistical Report. Available online at: https://restoreisight.org/wp-content/uploads/2020/04/2019-EBA-Stat-Report-FINAL.pdf (accessed May 10, 2020).
2. Mencucci R, Favuzza E, Marzili E, Cennamo M, Mazzotta C, Lucenteforte E, et al. Ultrathin descemet stripping automated endothelial keratoplasty versus Descemet membrane endothelial keratoplasty: a fellow-eye comparison. Eye Vis. (2020) 7:25. doi: 10.1186/s40662-020-00191-6
3. Dickman MM, Kruit PJ, Remeijer L, Van RJ, Van DLA, Wijdin RHJ, et al. A randomized multicenter clinical trial of ultrathin Descemet stripping automated endothelial keratoplasty (DSEA K) versus DSAEK. Ophthalmology. (2016) 123:2276–84. doi: 10.1016/j.ophtha.2016.07.036
4. Price MO, Jordan CS, Moore G, Price FW Jr. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part two: the statistical analysis of probability and risk factors. Br J Ophthalmol. (2009) 93:391–5. doi: 10.1136/bjo.2008.1 40038
5. Ang M, Soh Y, Htton HM, Mehta JS, Tan D. Five-year graft survival comparing Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. Ophthalmology. (2016) 123:1646–52. doi: 10.1016/j.ophtha.2016.04.049
6. Price MO, Price FW Jr. Endothelial keratoplasty - a review. Clin Exp Ophthalmol. (2010) 38:128–40. doi: 10.1111/j.1442-9071.2010.02213.x
7. Ishii N, Yamaguchi T, Yazu H, Satake Y, Yoshida A, Shimazaki J. Factors associated with graft survival and endothelial cell density after Descemet’s stripping automated endothelial keratoplasty. Sci Rep. (2016) 6:25276. doi: 10.1038/srep 25276
8. Terry MA, Aldave AJ, Szczotka-Flynn LB, Liang W, Ayala AR, Maguire MG, et al. Donor, recipient, and operative factors associated with graft success in the Cornea Preservation Time Study. Ophthalmology. (2018) 125:1700–9. doi: 10.1016/j.ophtha.2018.08.002
9. Ross KW, Stoeger CG, Rosenwasser GOD, O’Brien RC, Szczotka-Flynn LB, Ayala AR, et al. Prelamellar dissection donor corneal thickness is associated with Descemet stripping automated endothelial keratoplasty operative complications in the Cornea Preservation Time Study. Cornea. (2019) 38:1069–76. doi: 10.1097/ICO.0000000000002040
10. Lass JH, Benetz BA, Patel SV, Szczotka-Flynn LB, O’Brien R, Ayala AR, et al. Donor, recipient, and operative factors associated with increased endothelial cell loss in the Cornea Preservation Time Study. JAMA Ophthalmol. (2019) 137:185–93. doi: 10.1001/jamaophthalmol.2018.5669
11. Lass JH, Benetz BA, Verdier DD, Szczotka-Flynn LB, Ayala AR, Liang W, et al. Corneal endothelial cell loss 3 years after successful Descemet stripping automated endothelial keratoplasty in the Cornea Preservation Time Study: a randomized clinical trial. JAMA Ophthalmol. (2017) 135:1394– 400. doi: 10.1001/jamaophthalmol.2017.4970
12. Price MO, Fairchild KM, Price DA, Price FW Jr. Descemet’s stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. Ophthalmology. (2011) 118:725–9. doi: 10.1016/j.ophtha.2010.08.012
13. Mitry D, Bhogal M, Patel AK, Lee BS, Chai SM, Price MO, et al. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome. JAMA Ophthalmol. (2014) 132:742–49. doi: 10.1001/jamaophthalmology.2014.552
14. Shimazaki J, Amano S, Uno T, Maeda N, Yokoi N, Japan Bullous Keratopathy Study Group. National survey on bullous keratopathy in Japan. Cornea. (2007) 26:274–8. doi: 10.1097/ICO.0b013e318029e19
15. Nishino T, Kobayashi A, Yokogawa H, Mori N, Masaki T, Sugiyama K. A 10-year review of underlying diseases for endothelial keratoplasty (DSEA K/DMEK) in a tertiary referral hospital in Japan. Clin Ophthalmol. (2018) 12:1359–65. doi: 10.2147/OPHTH.170263
16. Takahashi A, Yamaguchi T, Tomida D, Nishisako S, Sasaki C, Shimazaki J. Trends in surgical procedures and indications for corneal transplantation over 27 years in a tertiary hospital in Japan. Jpn J Ophthalmol. (2021) 65:608– 15. doi: 10.1007/s10384-021-00849-1
17. Yazu H, Yamaguchi T, Aketa N, Higa K, Suzuki T, Yagi-Yaguchi Y, et al. Preoperative aqueous cytokine levels are associated with endothelial cell loss after Descemet’s stripping automated endothelial keratoplasty. Invest Ophthalmol Vis Sci. (2018) 59:612–20. doi: 10.1167/iovs.17-23049
18. Yamaguchi T, Higa K, Tsibota K, Shimazaki J. Elevation of preoperative recipient aqueous cytokine levels in eyes with primary graft failure after corneal transplantation. Mol Vis. (2018) 24:613–20.
19. Ibrahim O, Yagi-Yaguchi Y, Kakisu K, Shimazaki J, Yamaguchi T. Association of iris damage with reduction in corneal endothelial cell density after penetrating keratoplasty. *Cornea*. (2019) 38:268–74. doi: 10.1097/ICO.000000000001819

20. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. *Br J Cancer*. (2003) 89:2045–50. doi: 10.1038/sj.bjc.6601364

21. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. *Ann Surg.* (2003) 238:197–202. doi: 10.1097/01.sla.0000080822.22415.cb

22. Potapenko IO, Samolov B, Armitage MC, Byström B, Hjortdal J. Donor endothelial cell count does not correlate with Descemet stripping automated endothelial keratoplasty transplant survival after 2 Years of follow-up. *Cornea*. (2017) 36:649–54. doi: 10.1097/ICO.000000000001189

23. Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, et al. Global survey of corneal transplantation and eye banking. *JAMA Ophthalmol*. (2016) 134:167–73. doi: 10.1001/jamaophthalmol.2015.4776

24. Shimazaki J, Shinozaki N, Shimmura S, Holland EJ, Tsubota K. Efficiency and safety of international donor sharing: a single-center, case-controlled study on corneal transplantation. *Transplantation*. (2004) 78:216–20. doi: 10.1097/01.TP.0000080822.28962.4A

25. Yagi-Yaguchi Y, Yamaguchi T, Higa K, Suzuki T, Aketa N, Dogru M, et al. Association between corneal endothelial cell densities and elevated cytokine levels in the aqueous humor. *Sci Rep*. (2017) 7:13603. doi: 10.1038/s41598-017-14131-3

26. Romano V, Parekh M, Virgili G, Coco G, Leon P, Islein, K et al. Gender matching did not affect 2-year rejection or failure rates following DSAEK for Fuchs endothelial corneal dystrophy. *Am J Ophthalmol*. (2021) 235:204–10. doi: 10.1016/j.ajo.2021.09.029

27. Romano V, Tey A, Hill NM, Ahmad S, Britten C, Batterbury M, et al. Influence of graft size on graft survival following Descemet stripping automated endothelial keratoplasty. *Br J Ophthalmol*. (2015) 99:784–8. doi: 10.1136/bjo.2014-305648

28. Dirisamer M, Yeh R-Y, van Dijk K, Ham L, Dapena I, Melles GRJ. Recipient endothelium may relate to corneal clearance in Descemet membrane endothelial transfer. *Am J Ophthalmol*. (2012) 154:290–96.e1. doi: 10.1016/j.ajo.2012.02.032

29. Lagali N, Stenevi U, Claesson M, Fagerholm P, Hanson C, Weijdegard B, et al. Donor and recipient endothelial cell population of the transplanted human cornea: a two-dimensional imaging study. *Invest Ophthalmol Vis Sci.* (2010) 51:1898–904. doi: 10.1167/iovs.09-4066

30. Price MO, Baig KM, Brubaker JW, Price FW Jr. Randomized, prospective comparison of precut vs surgeon-dissected grafts for descemet stripping automated endothelial keratoplasty. *Am J Ophthalmol*. (2008) 146:36–41. doi: 10.1016/j.ajo.2008.02.024

31. Bourne WM, Nelson LR, Hodge DO. Continued endothelial cell loss ten years after lens implantation. *Ophthalmology*. (1994) 101:1014–22; discussion 1022–1023. doi: 10.1016/S0161-6420(94)31224-3

32. Kawai M, Inoue T, Inatani M, Tsboi N, Shobayashi K, Matsukawa A, et al. Elevated levels of monocle chemoreactant protein-1 in the aqueous humor after phacoemulsification. *Invest Ophthalmol Vis Sci*. (2012) 53:7951–60. doi: 10.1167/iovs.12-10231

33. Yamaguchi T, Higa K, Suzuki T, Nakayama N, Yagi-Yaguchi Y, Dogru M, et al. Elevated cytokine levels in the aqueous humor of eyes with bullous keratopathy and low endothelial cell density. *Invest Ophthalmol Vis Sci*. (2016) 57:954–62. doi: 10.1167/iovs.16-20187

34. Yagi-Yaguchi Y, Yamaguchi T, Higa K, Suzuki T, Yazu H, Aketa N, et al. Preoperative aqueous cytokine levels are associated with a rapid reduction in endothelial cells after penetrating keratoplasty. *Am J Ophthalmol*. (2017) 181:166–73. doi: 10.1016/j.ajo.2017.07.005

35. Yamaguchi T, Higa K, Yagi-Yaguchi Y, Ueda K, Noma H, Shirbata S, et al. Pathological processes in aqueous humor due to iris atrophy predispose to early corneal graft failure in humans and mice. *Sci Adv*. (2020) 6:eaaaz5195. doi: 10.1126/sciadv.aaz5195

36. Kitazawa K, Inatomi T, Tanioka H, Kawasaki S, Nakagawa H, Hieda O, et al. The existence of dead cells in donor corneal endothelium preserved with storage media. *Br J Ophthalmol*. (2017) 101:1725–30. doi: 10.1136/bjophthalmol-2017-10913

37. Pipparelli A, Thuret G, Toubeau D, He Z, Piselli S, Lefevre S, et al. Pan-corneal endothelial viability assessment: application to endothelial grafts pre-dissected by eye banks. *Invest Ophthalmol Vis Sci*. (2011) 52:6018–25. doi: 10.1167/iovs.10-6641

38. Nariey IN, Ng W, Sherrard ES, Steele AD. Posterior corneal folds and endothelial cell damage in human donor eyes. *Br J Ophthalmol*. (1989) 73:121–5. doi: 10.1136/bjo.73.2.121

39. McCarey BE, Edelhauser HF, Lynn MJ. Review of corneal endothelial specular microscopy for FDA clinical trials of refractive procedures, surgical devices, and new intraocular drugs and solutions. *Cornea*. (2008) 27:1–16. doi: 10.1097/ICO.0b013e31815892da

40. Annadanam A, Stoeger CG, Galloway JD, Hikes MT, Jun AS. Optical coherence tomography assessment of the cornea during corneal swelling: should the term "Descemet membrane folds" be reconsidered? *Cornea*. (2019) 38:754–7. doi: 10.1097/ICO.0b013e3181501908

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nishisako, Yamaguchi, Hirayama, Higa, Aoki, Sasaki, Noma and Shimazaki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.